Sangamo Therapeutics Inc (NASDAQ:SGMO)

3.56
Delayed Data
As of Nov 25
 +0.005 / +0.14%
Today’s Change
3.12
Today|||52-Week Range
8.76
-52.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$596.5M

Company Description

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Contact Information

Sangamo Therapeutics, Inc.
7000 Marina Boulevard
Brisbane California 94005
P:(510) 970-6000
Investor Relations:

Employees

Shareholders

Mutual fund holders36.82%
Other institutional26.27%
Individual stakeholders20.06%

Top Executives

Alexander D. MacraePresident, Chief Executive Officer & Director
Mark D. McClungChief Operating Officer & Executive Vice President
Prathyusha DurabaibuSenior VP, Chief Financial & Accounting Officer
R. Andrew RamelmeierExecutive Vice President-Technical Operations
Jason D. FontenotChief Scientific Officer & Senior Vice President